AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT06288321 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Standard Mydrin-P
Description: Standard Mydrin-P is the standard mydriatic used for retinopathy of prematurity exam as per our local usual practice.
Study NCT06016504 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Health Education
Description: Participate in an adaptive virtual consultation
Study NCT06016504 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Health Education
Description: Participate in a non-adaptive virtual consultation
Study NCT06016504 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Informational Intervention
Description: Given information-only
Study NCT06016504 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Survey Administration
Description: Ancillary studies
Study NCT06016504 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Survey Administration
Description: Ancillary studies
Study NCT04307329 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Monalizumab
Description: Monalizumab 750 mg every two weeks
Study NCT04307329 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Description: Trastuzumab 4 mg/kg every two weeks
Study NCT06303388 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Bruegger,s Exercise
Description: Bruegger's Exercise protocol along with conventional Physiotherapy.
Study NCT06303388 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Egoscue Exercise
Description: Egoscue Exercise along with conventional Physiotherapy.
Study NCT04940039 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Risperidone 3 mg
Description: Participants will receive 3 mg oral risperidone tablet once daily for 3 days.
Study NCT04940039 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paliperidone Palmitate 50 mg eq.
Description: Participants will receive 50 mg eq. PP1M IM injection for at least 17 weeks (maximum 25 weeks).
Study NCT04940039 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paliperidone Palmitate 75 mg eq.
Description: Participants will receive 75 mg eq. PP1M IM injection for at least 17 weeks.
Study NCT04940039 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paliperidone Palmitate 100 mg eq.
Description: Participants will receive 100 mg eq. PP1M IM injection for at least 17 weeks.
Study NCT04940039 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paliperidone Palmitate 150 mg eq.
Description: Participants will receive 150 mg eq. PP1M IM injection for at least 17 weeks.
Study NCT04940039 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paliperidone Palmitate 175 mg eq.
Description: Participants will receive 175 mg eq. PP3M IM injection up to 24 weeks.
Study NCT04940039 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paliperidone Palmitate 263 mg eq.
Description: Participants will receive 263 mg eq. PP3M IM injection up to 24 weeks.
Study NCT04940039 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paliperidone Palmitate 350 mg eq.
Description: Participants will receive 350 mg eq. PP3M IM injection up to 24 weeks.
Study NCT04940039 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paliperidone Palmitate 525 mg eq.
Description: Participants will receive 525 mg eq. PP3M IM injection up to 24 weeks.
Study NCT06464003 — intervention group
Intervention type: OTHER
Intervention: Questionnaire
Description: Malocclusion impact questionnaire
Study NCT05434962 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Cardiac resynchronization therapy
Description: Standard BiV-CRT The CRT-P/CRT-D device and leads should be implanted according to the physician's manual provided with the devices. Only locally approved Medtronic CRT-P/CRT-D generators will be used during the study. The LV lead should be implanted at a lateral or posterolateral CS branch in a basal or mid ventricular position confirmed by ortogonal fluoroscopic views (RAO and LAO 40º). Acceptable LV pacing threshold should be \<3V@0,5ms and phrenic nerve stimulation (PNS) margin should be >1V with respect to the pacing threshold.~LBBAP-CRT The CRT-P/CRT-D device and leads should be implanted according to the physician's standard practice. Only locally approved Medtronic CRT-P/CRT-D generators will be used during the study. During the implant procedure lead impedances, pacing and sensing parameters will be measured using a pacing system analyzer (PSA). For LBBAP, the Medtronic 3830 lead will be used. Acceptable LBBAP threshold should be \<2,5V@0,5ms
Study NCT05434962 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cardiac resynchronization therapy
Description: Standard BiV-CRT The CRT-P/CRT-D device and leads should be implanted according to the physician's manual provided with the devices. Only locally approved Medtronic CRT-P/CRT-D generators will be used during the study. The LV lead should be implanted at a lateral or posterolateral CS branch in a basal or mid ventricular position confirmed by ortogonal fluoroscopic views (RAO and LAO 40º). Acceptable LV pacing threshold should be \<3V@0,5ms and phrenic nerve stimulation (PNS) margin should be >1V with respect to the pacing threshold.~LBBAP-CRT The CRT-P/CRT-D device and leads should be implanted according to the physician's standard practice. Only locally approved Medtronic CRT-P/CRT-D generators will be used during the study. During the implant procedure lead impedances, pacing and sensing parameters will be measured using a pacing system analyzer (PSA). For LBBAP, the Medtronic 3830 lead will be used. Acceptable LBBAP threshold should be \<2,5V@0,5ms
Study NCT05447533 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Comprehensive geriatric assessment (CGA)
Description: Within 5 weekdays from date of randomization (not included) a standardized CGA with a tailor-made intervention will be performed in the allocated ward or at home by a geriatric team. Bedside Multidimensional Prognostic Index (MPI) will be performed.~A geriatric Clostridioides difficile infection checklist will be performed by local geriatrician and secure an early assessment of CDI and treatment strategy.~When indication: pre-treatment with vancomycin 125 mg x 4. Routine biochemical analyses for patients with Clostridioides difficile infection.~Evaluation of indication for faecal microbiota transplantation (FMT).~Criteria for FMT rely on the geriatric assessment and will be considered for the patient if the patient fulfil one of the following:~1. Severe index, recurrent or refractory CDI as defined by national clinical guidelines or~2. High risk patient according to CGA at first visit. High risk patient is defined frailty grade MPI-2 (moderate) or MPI-3 (severe).
Study NCT05447533 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Continued geriatric care
Description: Continued specialized geriatric care through 8 weeks of follow-up. Minimum of follow-up is 8 weeks from last FMT or start of vancomycin/fidaxomicin treatment.~Tailormade telephone contacts and/or visits in case of clinical exacerbation. Performed by local geriatric teams.~The geriatric department remains responsible for the CDI during 8 weeks of follow-up or until cured.
Study NCT05447533 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Faecal microbiota transplantation (FMT)
Description: When clinical indication for FMT, this will be delivered as 15-25 capsules (\~ 50 grams of donor faeces from one thoroughly screened healthy donor). If the patient is not admitted to hospital, FMT will be de-livered as home treatment via regional geriatric team or project manager and project nurse. If the patient has dysphagia diagnosed by dysphagia screening or carries a nasogastric tube, vancomycin and FMT can be delivered by naso-jejunal tube (Bengmark 10 Fr, Nutricia), requiring a referral to the Radiology department for verification of duodenal/jejunal tube placement. If available in the specific department, placement can be controlled via mobile x-ray.
Study NCT05447533 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard care
Description: Standard care: Patients are not contacted by the geriatric team. They receive usual treatment at the treating physician's discretion.
Study NCT04496986 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Fiberoptic Endoscopic Evaluation of Swallowing
Description: This procedure involves inserting a flexible laryngoscope that contains a light source and video camera on the end through the open passage of the nose towards the back of the throat in order to visualize the swallowing mechanism.
Study NCT04496986 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Simultaneous FEES and Videofluoroscopy instrumental swallowing exam
Description: This procedure involves inserting a flexible laryngoscope that contains a light source and video camera on the end through the open passage of the nose towards the back of the throat in order to visualize the swallowing mechanism. The participant will be asked to perform some voicing tasks, once completed, a videofluoroscopic swallowing exam will occur at the same time. This is like moving x-ray of the participant swallowing foods and liquids (barium).
Study NCT04496986 — intervention group
Intervention type: OTHER
Intervention: Voluntary Cough Peak Expiratory Flow (PEF) Testing
Description: Cough PEF will be performed to index a participant's physiologic airway defense capacity and strength. Testing will occur with the participant seated upright at 90 degrees using an analog peak flow meter with a one-way expiratory valve that prevents a participant from breathing air in from the device to reduce contamination.
Study NCT04496986 — intervention group
Intervention type: OTHER
Intervention: Reflex Cough Screen
Description: Participants will be seated upright and administered reflex cough testing via a disposable adult aerosol mask with an attached nebulizer that contains a solution to elicit a cough response.
Study NCT04496986 — intervention group
Intervention type: OTHER
Intervention: Lingual Pressure Testing
Description: Lingual strength will be evaluated using the Iowa Oral Pressure Instrument (IOPI). Participants will be seated upright, and the SLP will place the IOPI air-filled sensing bulb in the midline anterior position on the participant's tongue, posterior to the alveolar ridge.
Study NCT04496986 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Speech Testing
Description: Speech assessment will occur with the participant comfortably seated headset microphone with a lapel windscreen connected to a TASCAM DR40 to allow for high-quality audio recordings. Individuals will be asked to perform two maximal performance speech tasks that include vowel prolongation of /a/, and a Diadochokinetic (DDK) rate task to examine SMR for production of the word buttercup.
Study NCT06334302 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Omega Galil Hazelnut Chocolate Spread O'Sweet Spread
Description: Omega Galil O'Sweet hazelnut cocoa spread is composed of 8% sucrose, 26% MCT oil, 6% cocoa butter, 6% cocoa powder, 10% Hazelnut paste, 24% fibers, 13% rice flour. It contains a total of 27.3 gram carbohydrates/ 100gram, 520 kcals/100 grams, and very low estimated GL according to healthy adults
Study NCT06334302 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Active Control-Nutella hazelnut cocoa spread
Description: Nutella hazelnut cocoa spread is composed of 56% sugar, 30% vegetable fat, 13% Hazelnut paste, milk powder (8.7%), and cocoa powder (7.4%), containing a total of 57.5 grams carbohydrates /100grams, 532 kcals/100 grams, and an estimated GL of 4
Study NCT04723862 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Spironolactone
Description: Spironolactone is an androgen-receptor blocker commonly used (off-label) for hyperandrogenism. The spironolactone dose will be 50 mg taken orally twice daily (for two weeks before admission to the Clinical Research Unit).
Study NCT04723862 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo contains only inert ingredients and is not expected to exert any direct physiological effects.
Study NCT05381987 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Radial shockwave therapy
Description: Shockwave Storz Medical device, Doulith SD1, Tower (BT)
Study NCT05381987 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Radial shockwave therapy
Description: Shockwave Storz Medical device, Doulith SD1, Tower (BT)
Study NCT05649033 — intervention group
Intervention type: OTHER
Intervention: data collection
Description: Work-related stress evaluation
Study NCT06104202 — intervention group
Intervention type: OTHER
Intervention: Early Maladaptive Schemas
Description: Compare profiles of maladaptive early patterns using scores :~* Young Schema Questionnaire Short form~* Maslach Burnout Inventory~* Montgomery-Asberg depression rating Scale~* White Bear Suppression Inventory
Study NCT05007769 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ramucirumab
Description: Will be supplied by Lilly Oncology, free of charge to the participant
Study NCT05007769 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Atezolizumab will be commercially available.
Study NCT05007769 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: N-803
Description: Will be supplied free of charge to the participants by ImmunityBio
Study NCT05653323 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VX-993
Description: Suspension for oral administration.
Study NCT05653323 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Suspension for oral administration.
Study NCT05351853 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Omnivore
Description: This study will evaluate effects of plant based diets (vegan and vegetarian). 60 omnivore individuals will be included. 20 of the participants will continue their omnivore diet as control group. 20 of the participants will change their diet to vegetarian, and 20 of them will change their diet to vegan.
Study NCT05351853 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Vegetarian
Description: 20 of the participants will change their diet to vegetarian diet. In this group participants will not eat any meat or meat product but can eat/drink milk products, egg and other animal products.
Study NCT05351853 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Vegan
Description: 20 of the participants will change their diet to vegan diet. In this group participants will not eat any kind of animal products.
Study NCT05342220 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Remote ischemic preconditioning
Description: Remote ischemic preconditioning through inflation of a blood pressure cuff to pressure values > 200mmHg for 5 minutes followed by 5 minutes of reperfusion (3 times each) before electrocardioversion Electrical cardioversion for atrial fibrillation (100, 150, 200 Joule)
Study NCT05342220 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Sham preconditioning
Description: Inflation of a blood pressure cuff to pressure values \~ 10mmHg for 5 minutes followed by 5 minutes of reperfusion (3 times each) before electrocardioversion
Study NCT04492345 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Isokinetic reeducation
Description: Conventional rehabilitation session and isokinetic during 7 weeks
Study NCT04492345 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Conventional reeducation
Description: Conventional rehabilitation session during 7 weeks
Study NCT05032768 — intervention group
Intervention type: RADIATION
Intervention: post-operative radiotherapy
Description: Breast cancer patients who have received reconstructive surgery will receive post-operative radiotherapy.
Study NCT06445309 — intervention group
Intervention type: OTHER
Intervention: Sensory test of functional plant-based drink
Description: Once the volunteers have been recruited, a telephone interview lasting less than 10 minutes will be carried out where what the study consists of will be explained as well as the information sheet for the participant will be read to them so that they understand what the study consists of. study. Once the necessary questions have been asked according to the inclusion criteria, if the participant enters the study, data such as name, surname, age, gender, smoker, consumer of vegetable drinks, pathologies and contact information will be collected. If the participant does not enter the study, their personal data will no longer be collected and they will be informed that according to the exclusion criteria they can no longer participate in the study. Once these data are obtained, it will be randomized using the EXCEL program.
Study NCT06385405 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Individualized alpha frequency Transcranial Magnetic Stimulation (αTMS) Treatment
Description: The target site for alpha frequency Transcranial Magnetic Stimulation (αTMS) was identified based on alterations in alpha band spectral connectivity, which were measured using four frontal electroencephalography (EEG) channels (F1, F3, F5, FC3) subsequent to 10Hz transcranial magnetic stimulation (TMS). Alpha band spectral connectivity refers to the degree of similarity between the spectral waveforms of the alpha band across channels. The alpha frequency stimulation rate was defined as the highest spectral peak within the alpha band ranging from 7 to 13 Hz of the target channel. Each treatment cycle consisted of 20 daily sessions over a 4-week span, and stimulation was administered for 2 seconds every minute for a total duration of 20 minutes at 80% of the individual's motor threshold.
Study NCT06385405 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: 10Hz-frequency TMS treatment over the left dorsolateral prefrontal cortex (DLPFC)
Description: Prefrontal Transcranial Magnetic Stimulation (TMS) therapy repeated daily over 4 weeks (20 sessions) is US Food and Drug Administration (FDA) approved for treating Major Depressive Disorder in adults who have not responded to prior antidepressant medications. The strongest evidence supports high-frequency treatment over the left dorsolateral prefrontal cortex (DLPFC). The common stimulation frequency is 10Hz. It is usually applied for a duration of 4 weeks, 5 days a week.
Study NCT06503029 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Invisalign Cleaning Crystals
Description: Invisalign Cleaning Crystals are used as a cleaning method for orthodontic clear aligners. It includes Sodium Sulfate as an active ingredient.
Study NCT06503029 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Fittey Dent Cleaning Tablet
Description: Fittey Dent Cleaning Tablet is used as a cleaning method for orthodontic clear aligners. It includes Sodium Perborate as an active ingredient.
Study NCT06503029 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Listeren Mouthwash
Description: Listeren Mouthwash is used as a cleaning method for orthodontic clear aligners. It includes Eucalyptol and Menthol as active ingredients.
Study NCT06503029 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Toothbrush and Water
Description: Toothbrush and water is used as a cleaning method for orthodontic clear aligners that as recommended by the aligner manufacturer.
Study NCT05210296 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercises
Description: Therapeutic exercise will be applied to the elderly
Study NCT05039398 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as usual
Description: The workplace receives dialogue and guidance during the WEA workplace inspection as per WEA standard practice.
Study NCT05039398 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dialogue and guidance over telephone
Description: In addition to receiving dialogue and guidance during WEA workplace inspection as standard practice by the WEA, the Dialogue and guidance over telephone receives up to 2 hours of supplemental dialogue and guidance after WEA inspection with the WEA inspector. This is conducted over the telephone.
Study NCT05039398 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dialogue and guidance at physical meeting
Description: In addition to receiving dialogue and guidance during WEA workplace inspection as standard practice by the WEA, the Dialogue and guidance at physical meeting receives up to 2 hours of supplemental dialogue and guidance after WEA inspection with the WEA inspector. This is conducted as a physical meeting.
Study NCT04560569 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Albuvirtide
Description: Long-Acting HIV-1 Fusion Inhibitor (chemically modified peptide targeting HIV-1 gp41)
Study NCT04560569 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 3BNC117 Antibody
Description: Recombinant, fully human mAb of the IgG1κ isotype that specifically binds to HIV-1 gp120
Study NCT06209671 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: INS19 CAR-T Cells
Description: INS19 CAR-T Cells, 1-2×10\^7 cells, treatment follows a lymphodepletion. Drug: Fludarabine Recommendation: 25-30 mg/m\^2/day (D-5\~D-3), determined by tumor burden at baseline. Drug: Cyclophosphamide Recommendation: 250-300 mg/m\^2/day (D-5\~D-3), determined by tumor burden at baseline.
Study NCT06274671 — intervention group
Intervention type: OTHER
Intervention: Magnetic Resonance Imaging
Description: A Magnetic Resonance Imaging (duration: about 60 minutes) with research sequences for the visualization of alterations of the glymphatic system.
Study NCT05629195 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: tunneled PICC
Description: PICC catheter is inserted into the superior vena cava through the upper brachial vein by establishing a subcutaneous tunnel
Study NCT05629195 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: tunneled PICC
Description: PICC catheter is inserted into the superior vena cava through the upper brachial vein by establishing a subcutaneous tunnel
Study NCT06634680 — intervention group
Intervention type: PROCEDURE
Intervention: Procedure: Selection of parent(mother or father) according to children preference
Description: Children will choose the parent who will accompany them.
Study NCT06634680 — intervention group
Intervention type: PROCEDURE
Intervention: Procedure: Both parents will accompany the children.
Description: Both parents will accompany the children.